Module 1: Chronic Lymphocytic Leukemia (CLL)

DISCUSSION TOPICS

• Incidence of genetic abnormalities in CLL (eg, 17p deletions, TP53 and IGHV gene mutations) and implication for long-term prognosis
• Selection of up-front treatment for CLL in younger and older patients with normal and high-risk cytogenetics
• Integrating ibrutinib into the treatment algorithm for CLL: Activity and side-effect profile, including atrial fibrillation and risk of bleeding
• Management of relapsed/refractory CLL: Incorporation of venetoclax for patients with del(17p) and potential role in non-del(17p) disease
• Risk of and preemptive measures to prevent tumor lysis syndrome with venetoclax
• Novel combination strategies currently under investigation

Module 2: Hodgkin Lymphoma (HL)

DISCUSSION TOPICS

• Relative benefits and risks of various combination chemotherapy regimens for newly diagnosed advanced-stage HL
• Mechanism of action of brentuximab vedotin (BV) and role in the post-transplant consolidation and relapsed/refractory settings; potential incorporation into up-front treatment
• Incidence and management of peripheral neuropathy and other toxicities associated with BV in HL
• Biologic rationale for the efficacy of immune checkpoint inhibitors in HL and integration of nivolumab and pembrolizumab into the treatment algorithm for relapsed/refractory disease
• Side effects and toxicities of anti-PD-1 antibodies; use in patients with prior autoimmune disorders
• Use of nonchemotherapy approaches for elderly patients and those with comorbidities

Module 3: Follicular Lymphoma (FL)

DISCUSSION TOPICS

• Selection of treatment, including “watch and wait” and rituximab monotherapy, for patients with newly diagnosed FL
• Comparative safety and efficacy of subcutaneous versus intravenous administration of rituximab in FL and other lymphomas
• Integration of obinutuzumab-based induction and maintenance therapy for patients with previously untreated FL
• Available research data and ongoing evaluation of rituximab/lenalidomide (R²)
• Appropriate integration of copanlisib into current treatment algorithms; recognition, prevention and management of toxicities

Module 4: Diffuse Large B-Cell Lymphoma (DLBCL)

DISCUSSION TOPICS

• Molecular subtypes of DLBCL and impact on prognosis and potential treatment course
• Management of relapsed/refractory disease, including the use of lenalidomide
• Recent FDA approval and emerging clinical role of chimeric antigen receptor (CAR) T-cell therapy for patients with DLBCL and other aggressive lymphomas
• Practical considerations in the administration of CAR T-cell therapy
• Novel agents and strategies currently under investigation in relapsed/refractory DLBCL

Module 5: Mantle Cell Lymphoma (MCL)

DISCUSSION TOPICS

• Clinical considerations and disease-related factors in the determination to administer treatment versus observe off therapy in patients with newly diagnosed MCL
• Selection of front-line and maintenance therapy for younger and older patients with newly diagnosed MCL
• Sequencing of available treatment options for relapsed/refractory MCL: bortezomib, lenalidomide, ibrutinib, et cetera
• Counseling patients receiving oral therapies regarding adherence
• Mechanism of action and tolerability of the recently FDA-approved second-generation BTK inhibitor acalabrutinib

Module 6: T-Cell Lymphoma (TCL)

DISCUSSION TOPICS

• Up-front therapy for younger and older patients with TCL; role of autologous stem cell transplant
• Recent FDA approval and available safety and efficacy data with BV for patients with CD30-positive TCL
• Patient- and/or disease-specific factors guiding the sequence and selection of BV, pralatrexate and romidepsin in TCL

Special Session: Dr Basch

Using innovative communication strategies to assist nurses and other caregivers in meeting the needs of patients with cancer